Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.0290
Abstract: This cohort study assesses the association of upfront peptide receptor radionuclide therapy (PRRT) vs upfront chemotherapy or targeted therapy with progression-free survival among patients in Italy with enteropancreatic neuroendocrine tumors who experienced disease progression after… read more here.
Keywords: receptor radionuclide; association upfront; progression; peptide receptor ... See more keywords
Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-018-4209-7
Abstract: PurposePeptide receptor radionuclide therapy (PRRT) is mostly administered using a fixed injected activity (IA) per cycle. This empiric regime results in highly variable absorbed doses to the critical organs and undertreatment of the majority of… read more here.
Keywords: initial results; response; 177lu octreotate; prrt trial ... See more keywords
Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series
Sign Up to like & getrecommendations! Published in 2019 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-019-04389-2
Abstract: PurposePeptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) is an effective therapy for metastatic neuroendocrine neoplasia (NEN), but therapy-related myeloid neoplasms (t-MN) remain of concern. The study reviewed the clinicopathological features and outcomes of patients who developed t-MN.MethodsRetrospective… read more here.
Keywords: therapy; prrt prcrt; radionuclide chemoradionuclide; receptor radionuclide ... See more keywords
Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy
Sign Up to like & getrecommendations! Published in 2021 at "Current Oncology Reports"
DOI: 10.1007/s11912-021-01037-7
Abstract: Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3] octreotate is an effective and safe second- or third-line treatment option for patients with low-grade advanced gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN). In this review, we will focus on… read more here.
Keywords: radionuclide therapy; prrt; receptor radionuclide; receptor ... See more keywords
Peptide receptor radionuclide therapy after NETTER-1 clinical trial: what should not be left behind
Sign Up to like & getrecommendations! Published in 2019 at "Clinical and Translational Imaging"
DOI: 10.1007/s40336-019-00327-2
Abstract: Peptide receptor radionuclide therapy (PRRT) is an established therapy that takes advantage of the over-expression of somatostatin receptors (SSTRs) on neuroendocrine tumor cell surface, to vehicle radioactivity on cancer tissues. Approximately 80% of neuroendocrine tumors… read more here.
Keywords: radionuclide; receptor radionuclide; therapy; radionuclide therapy ... See more keywords
Neoadjuvant strategies for advanced pancreatic neuroendocrine tumors: should combined chemotherapy and peptide receptor radionuclide therapy be the preferred regimen for maximizing outcome?
Sign Up to like & getrecommendations! Published in 2018 at "Nuclear Medicine Communications"
DOI: 10.1097/mnm.0000000000000776
Abstract: With the evolution of peptide receptor radionuclide therapy (PRRT) in the mainstream management of metastatic/advanced neuroendocrine tumors (NETs), one area of particular interest is to define its place in the neoadjuvant setting of pancreatic NET… read more here.
Keywords: medicine; neuroendocrine tumors; receptor radionuclide; radionuclide therapy ... See more keywords
Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting
Sign Up to like & getrecommendations! Published in 2018 at "Nuclear Medicine Communications"
DOI: 10.1097/mnm.0000000000000926
Abstract: Background and aims Functioning and symptomatic disease resistant to conventional therapies constitutes a subset amongst neuroendocrine tumors (NETs) that are commonly considered for peptide receptor radionuclide therapy (PRRT). The aim of this study was to… read more here.
Keywords: progressive symptomatic; prrt; neuroendocrine tumors; receptor radionuclide ... See more keywords
Renal protection during 177lutetium DOTATATE molecular radiotherapy in children: a proposal for safe amino acid infusional volume during peptide receptor radionuclide therapy
Sign Up to like & getrecommendations! Published in 2021 at "Nuclear Medicine Communications"
DOI: 10.1097/mnm.0000000000001497
Abstract: Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues such as 177-lutetium DOTATATE is an effective treatment modality for neuroendocrine tumours, paragangliomas, and neuroblastomas. However, renal and haematopoietic toxicities are the major limitations of this… read more here.
Keywords: radionuclide therapy; amino; peptide receptor; amino acid ... See more keywords
A dosimetric comparison of systemic peptide receptor radionuclide therapy and intra-arterial peptide receptor radionuclide therapy in patients with liver dominant gastroenteropancreatic neuroendocrine tumours.
Sign Up to like & getrecommendations! Published in 2023 at "Nuclear medicine communications"
DOI: 10.1097/mnm.0000000000001696
Abstract: Objectives Intra-arterial radionuclide therapy (IART) treatment allows direct delivery of 177Lu-DOTATATE to the overexpressed somatostatin-positive neuroendocrine liver metastases, which led to higher tumour concentration compared with systemic radionuclide therapy (SRT). The aim was to evaluate… read more here.
Keywords: receptor radionuclide; radionuclide therapy; peptide receptor; therapy ... See more keywords
Pheochromocytomatosis Treated With Peptide Receptor Radionuclide Therapy.
Sign Up to like & getrecommendations! Published in 2022 at "Clinical nuclear medicine"
DOI: 10.1097/rlu.0000000000003973
Abstract: ABSTRACT Pheochromocytomatosis refers to pheochromocytoma tumorlets developed as a result of seeding of tumor cells around the surgical bed due to intraoperative tumor capsule rupture and tumor cell spillage. As pheochromocytomatosis is relatively rare, optimal… read more here.
Keywords: receptor radionuclide; peptide receptor; radionuclide therapy; pheochromocytomatosis ... See more keywords
Peptide Receptor Radionuclide Therapy in Patients With Advanced Progressive Medullary Thyroid Cancer
Sign Up to like & getrecommendations! Published in 2023 at "Clinical Nuclear Medicine"
DOI: 10.1097/rlu.0000000000004539
Abstract: Purpose Progressive metastatic medullary thyroid carcinoma (MTC) is often characterized by rapid disease progression and poor prognosis, with only few therapeutic options available. Peptide receptor radionuclide therapy (PRRT) has demonstrated remarkable success in the management… read more here.
Keywords: mtc; receptor radionuclide; patients advanced; peptide receptor ... See more keywords